4563.T

Healthcare Biotechnology

AnGes, Inc.

¥34.00

-1.00 -2.86% today

Price History

Not enough data

Key Stats

Market Cap

13.56B

Avg Volume

1.66M

EPS

-¥9.22

52W High

¥93.00

52W Low

¥34.00

Div. Yield

0.0%

Valuation

P/B Ratio

66.15

P/S Ratio

14.10

EV/EBITDA

-2.49

EV/Revenue

15.38

Margins

Gross Margin 41.4%

Operating Margin (581.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

22.0%

Return on Equity

(214.6%)

Return on Assets

(79.1%)

Liquidity & Leverage

Current Ratio

0.95

Quick Ratio

0.15

Debt / Equity

3.52

Total Cash

281.00M

Total Debt

722.00M

About

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.